Ebola — DR Congo
The new vaccine takes a novel approach, according to the study. The researchers designed a bivalent, spherical Ebola virus-like particle (VLP) that incorporates 2 genetically diverse glycoproteins (one each from the Zaire Ebola virus and Sudan Ebola virus) on a spherical core.
This approach will not cause illness in the recipient as the VLPs lack the genetic material and do not multiply. The vaccine works by stimulating immune responses against Ebola that generate virus-fighting antibodies
…
